So how does a man work with his doctor to get that very information? He must first learn from his doctor more about the connection between the pathophysiology and detection of prostate cancer. By obtaining the facts on that subject, a man can better appreciate the need for multiple diagnostic tests. Often only a series of tests can use to advantage the link between the pathophysiology and detection of prostate cancer.
At the present time a series of PSA tests offers the surest evidence for or against rapid growth of a prostate cancer tumor. That information helps with cancer management. Still, doctors would like to have access to even more information. Ongoing clinical trials are seeking to provide doctors with that information.
Those clinical trials highlight again the link between the pathophysiology and detection of prostate cancer. Those tests will define more than just the newest ways to detect prostate cancer. They will also help doctors to discover the latest methods for the stage of a prostate cancer tumor.
One such clinical trial has divided the tested patients into two groups. One group has received both spectroscopic analyses, in addition to an MRI. A second group of men did no more than lay on the table in an MRI lab; those men did not become the object of a spectroscopy analysis.
So what is the purpose of that trial? It is designed to assess the ideal method for measuring the size and shape of a prostate tumor. Information about that size and shape can guide health professionals in selecting the optimal treatment for any given prostate cancer patient.
While those clinical trails are still in progress, other clinical trials have been initiated. Those additional clinical trials are looking at molecular biology tools, and how those tools might be used to better diagnose prostate cancer. The hope is that information about the molecular biology of a tumor will help health professionals to develop a more effective treatment.
The search for more effective treatments has focused on the need for more individualized treatment. Such individualized treatments represent a new era of prostate cancer treatment. Still those new treatments can not be approved without a study of the results from the ongoing clinical trails.
Those trial results will reveal the degree to which individualized prostate cancer might
be better tolerated by the male patients. Those results will add to the information discussed by doctors and patients when they prepare to examine the available information about the patient’s tumor pathophysiology and his own test results.